Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 7/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.48 |
| ▸ | MGLL | Q99685 | 6/20 | 0.42 |
| ▸ | FAAH | O00519 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | XBP1 | P17861 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1413287 | 0.95 | PTGS1 (0.40) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL4450426 | 0.90 | PTGS1 (0.36) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL20589363 | 0.85 | PRKCA (0.38) | LMNAMAPTPKMMEN1KMT2A | |
| SCHEMBL30402863 | 0.81 | — | — | |
| SCHEMBL28226110 | 0.81 | GSK3A (0.44) | ALDH1A1LMNAMAPTPKMHPGD | |
| SCHEMBL3628006 | 0.79 | PRKCA (0.49) | PRKCA | |
| SCHEMBL180318 | 0.79 | PRKCA (0.49) | PRKCA | |
| SCHEMBL6910643 | 0.78 | PTGS1 (0.51) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL977159 | 0.78 | MAP3K14 (0.38) | LMNAMAPTPKMSMN1; SMN2MEN1 | |
| SCHEMBL29412566 | 0.78 | MGLL (0.46) | PTGS1PTGS2MGLLFAAHALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719485-A1 | ANTIBODY-DRUG CONJUGATES FOR TREATING INFECTIONS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) | Taimed Biologics Inc. (TW) | 2026-04-08 | — | — | EP | claimed |
| EP-4642491-A1 | METHOD FOR GLYCOPROTEIN MODIFICATION | Honeybear Biosciences Inc. (TW) | 2025-11-05 | — | — | EP | claimed |
| US-20240398969-A1 | ANTIBODY-DRUG CONJUGATES FOR TREATING INFECTIONS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) | TAIMED BIOLOGICS INC. (TW) | 2024-12-05 | — | — | US | claimed |
| WO-2024245401-A1 | ANTIBODY-DRUG CONJUGATES FOR TREATING INFECTIONS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) | TAIMED BIOLOGICS INC. (CN) | 2024-12-05 | — | — | WO | claimed |
| US-20240238432-A1 | METHOD FOR GLYCOPROTEIN MODIFICATION | HONEYBEAR BIOSCIENCES INC. (TW) | 2024-07-18 | — | — | US | claimed |
| EP-0895082-B1 | Bubble jet method for spotting probes on a solid support and method of manufacturing probe arrays. | CANON KK (JP) | 2003-09-24 | — | — | EP | claimed |
| US-20030059817-A1 | Spotting probe can bind preferentially to target nucleotide squences on solid support; provide liquid containing probe, deposit on solid support, form spot of probe on solid support | OKAMOTO TADASHI (JP) | 2003-03-27 | — | — | US | claimed |
| US-20020146715-A1 | Spotting probe preferentially bound to solid support; obtain liquid containing probe, apply to surface of solid support, allow stain to form on solid support | OKAMOTO TADASHI (JP) | 2002-10-10 | — | — | US | claimed |
| EP-0895082-A2 | Method of spotting probe on solid support, probe array and method of manufacturing thereof, and method of detecting target substance and method of identifying structure of target substance using probe array | CANON KABUSHIKI KAISHA (JP) | 1999-02-03 | — | — | EP | claimed |
| EP-0367166-A1 | Modified interleukin-2 and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1990-05-09 | — | — | EP | claimed |
| EP-4719485-A1 | ANTIBODY-DRUG CONJUGATES FOR TREATING INFECTIONS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) | Taimed Biologics Inc. (TW) | 2026-04-08 | — | — | EP | disclosed |
| US-20260049991-A1 | SINGLE-MOLECULE PEPTIDE SEQUENCING USING GUANIDINYLATING AGENTS | GLYPHIC BIOTECHNOLOGIES INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260049159-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS THERAPEUTICS, INC. (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4655289-A1 | SINGLE-MOLECULE PEPTIDE SEQUENCING USING GUANIDINYLATING AGENTS | Glyphic Biotechnologies, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| EP-4642491-A1 | METHOD FOR GLYCOPROTEIN MODIFICATION | Honeybear Biosciences Inc. (TW) | 2025-11-05 | — | — | EP | disclosed |
| EP-0575906-A2 | Sandwich immunoassay of beta-N-acetylglucosaminidase and monoclonal antibody used therein | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1993-12-29 | — | — | EP | disclosed |
| EP-0328690-A1 | METHOD FOR DIAGNOSING CHRONIC ARTICULAR RHEUMATISM | FUJI YAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 1989-08-23 | — | — | EP | disclosed |
| EP-0054685-B1 | HYDROPHILIC LATEX PARTICLES, PROCESS FOR THEIR PREPARATION AND THEIR USE | Roche Diagnostics GmbH (DE) | 1986-07-09 | — | — | EP | disclosed |
| US-4415700-A | EMULSION POLYMERIZATION OF AN UNSATURATED EPOXIDE CARRIERS; IMMUNOASSAY; MEDICAL DIAGNOSIS | BOEHRINGER MANNHEIM GMBH (DE) | 1983-11-15 | — | — | US | disclosed |
| EP-0054685-A2 | Hydrophilic latex particles, process for their preparation and their use | Roche Diagnostics GmbH (DE) | 1982-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049991-A1 | SINGLE-MOLECULE PEPTIDE SEQUENCING USING GUANIDINYLATING AGENTS | CHAMP1, S100A11, TFIP11 | PTGS1 3468/4885PTGS2 3866/4885MGLL 4085/4885 |
| US-20240398969-A1 | ANTIBODY-DRUG CONJUGATES FOR TREATING INFECTIONS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) | CD4, FCGR3B, FCGR1A | PTGS1 4202/4885PTGS2 4455/4885MGLL 4710/4885 |
| US-20240238432-A1 | METHOD FOR GLYCOPROTEIN MODIFICATION | SIGLEC7, FUT5, FUT6 | PTGS1 3702/4885PTGS2 3230/4885MGLL 681/4885 |
| US-20260049159-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | ALK, CD2, TGFBR2 | PTGS1 4395/4885PTGS2 4272/4885MGLL 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.